Angex Pharmaceutical

Angex Pharmaceutical is a clinical-stage biotechnology company focused on developing next-generation antibody-drug conjugates (ADCs) for the treatment of solid tumors. The company's lead program, AGX101, is a first-in-class ADC targeting Plexin-B1, a protein highly expressed in various cancers including breast, prostate, and lung, while showing limited expression in healthy tissues. Founded as a spin-out from the University of Queensland and Mater Research, Angex leverages deep expertise in tumor biology to create precision therapies that deliver potent cytotoxic payloads directly to cancer cells. The company is backed by prominent life science investors and is advancing its pipeline toward first-in-human clinical trials.